The abstract is read at the publisher; the summary is JClub's.
KDM3B is a critical epigenetic dependency in cholangiocarcinoma, and its loss suppresses colony formation, proliferation, and migration across intra- and extrahepatic tumor models.
- Why it matters: Many cholangiocarcinoma patients lack druggable mutations, leaving non-mutational epigenetic mechanisms and therapeutic opportunities poorly defined.
- What they did: Across multiple patient cohorts, KDM gene families were upregulated, with KDM3B linked by multi-omics to ErbB activation; KDM3B binds the ERBB3 promoter to remove repressive H3K9me2 marks.
- The result: In vivo pharmacologic inhibition of the KDM3B downstream ERBB-Akt regulatory axis suppressed cholangiocarcinoma xenograft growth, and high KDM3B–ERBB3 coupling reshaped the tumor niche toward a pro-invasive microenvironment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.